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Abstract
Meta-analysis of clinical trials targeting rare events face particular challenges when the data lack adequate number of
events and are susceptible to high levels of heterogeneity. The standard meta-analysis methods (DerSimonian Laird (DL)
and Mantel–Haenszel (MH)) often lead to serious distortions because of such data sparsity. Applications of the methods
suited to specific incidence and heterogeneity characteristics are lacking, thus we compared nine available methods in a
simulation study. We generated 360 meta-analysis scenarios where each considered different incidences, sample sizes,
between-study variance (heterogeneity) and treatment allocation. We include globally recommended methods such as
inverse-variance fixed/random-effect (IV-FE/RE), classical-MH, MH-FE, MH-DL, Peto, Peto-DL and the two extensions
for MH bootstrapped-DL (bDL) and Peto-bDL. Performance was assessed on mean bias, mean error, coverage and
power. In the absence of heterogeneity, the coverage and power when combined revealed small differences in meta-
analysis involving rare and very rare events. The Peto-bDL method performed best, but only in smaller sample sizes
involving rare events. For medium-to-larger sample sizes, MH-bDL was preferred. For meta-analysis involving very rare
events, Peto-bDL was the best performing method which was sustained across all sample sizes. However, in meta-
analysis with 20% or more heterogeneity, the coverage and power were insufficient. Performance based on mean bias
and mean error was almost identical across methods. To conclude, in meta-analysis of rare binary outcomes, our results
suggest that Peto-bDL is better in both rare and very rare event settings in meta-analysis with limited sample sizes.
However, when heterogeneity is large, the coverage and power to detect rare events are insufficient. Whilst this study
shows that some of the less studied methods appear to have good properties under sparse data scenarios, further work
is needed to assess them against the more complex distributional-based methods to understand their overall
performances.
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1 Introduction
Meta-analysis (MAs) of binary data encounter problems when proportions of events are few.1 This is a particular
issue in MAs of adverse events that are associated with biomedical interventions.2 Difficulties often arise when
analysis is done either at patient level using individual patient data or at the study level using just aggregate data
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from each trial. We concentrate here on MAs of study-level summaries, which is far more common in the
assessment of adverse events, though patient-level analysis is to be preferred when data are available.3
The methods used when performing MAs of binary data are frequently done using the standard inverse-
variance fixed-effects model which is based on large-sample normal approximation, or fixed-effects methods
based on exact distributional theory such as the Mantel–Haenszel (MH)4 or Peto model,5 or the standard
random-effects DerSimonian–Laird (DL) model.6 Because these methods lack power to investigate the incidence
of rare events and are mostly based on large sample normal approximation particularly inverse-variance,7,8 their
statistical properties for estimating treatment effects are often judged as suboptimal either through results being
biased, confidence intervals being inappropriately wide or statistical power being too low to detect any true
differences. One leading cause of this bias is the estimation of the between-study variance (s2),9 which often
displays uncertainty in MAs when there are few studies involved.10
Several simulation studies have evaluated the performances of these mainstream methods for MAs11–13 and
shown that the estimate of s2 is particularly inaccurate when the number of included studies is small. However,
evidence of heterogeneity estimation across different sample size settings with varying low levels of incidence (i.e.
rare events) and imbalanced treatment allocations is currently lacking.
The Cochrane guidelines (Version 6.1, 2020) recommend the use of methods which are mostly accessible in
Review Manager (RevMan); software developed by the Nordic Cochrane Centre and is free-to-access.8
Specifically, the guideline suggests that when the event rate is below 1%,14 the ‘Peto odds ratio’ method is
considered the least biased and most powerful method and provides the best confidence interval coverage.5
The method is also thought to perform well when treatment and control group sizes within studies are balanced
and treatment effects are small. In other circumstances, when event risks are above 1% and for MAs involving
many studies with imbalanced treatment groups; the MH odds ratio (OR) without continuity correction, logistic
regression and exact methods are considered to be better performing.15 However, there are two shortcomings
when using these methods: (i) not all of them are available in RevMan, in particular, the MH without continuity
correction, logistic regression and exact methods, and (ii) when heterogeneity are present, meta-analysts often
have to revert from inverse-variance weighting to a random-effects DL, to reduce bias in estimation. But, there are
still some obvious shortcomings of random-effects methods, as they are based on large-sample variance
approximation.1
Most recently, there have been several new methods proposed for improved estimation of s2. These include
maximum likelihood, profile likelihood and restricted maximum likelihood or non-parametric ‘permutations’
method.16 More specifically, a non-parametric bootstrap of the DL estimator was shown to be a better performer
in small MAs that were falsely assumed to be homogenous under the standard DL model.12,17 This non-
parametric bootstrap of the DL has now been extended for both the MH and Peto models, but very little is
known about the performances of these methods in MAs involving rare events whilst compounded with the issue
of heterogeneity. As these methods are easily accessible and applicable, it is important to assess whether they
could support or improve the current recommendations on MAs of rare events.
The focus of this study is to evaluate the use of mainstream fixed- and random-effects MAs methods including
two non-parametric bootstrap extensions for analysing rare or very rare outcomes, in a simulation study covering
typical scenarios for rare adverse events or rare diseases. The paper is organised as follows. In section 2, we
descriptively assess other similar simulation studies to highlight research gaps and limitations, which we are
attempting to address in this work. In section 3, we discuss the various meta-analytic methods used for estimating
relevant model parameters. In section 4, we report on the simulation study and introduce the tools used to
measure the performance of the methods across the simulated scenarios. In section 5, findings are illustrated in
tables or graphically, and in section 6, we conclude and provide recommendations for practical work in the future.
2 Literature review of simulation studies on rare events
Several simulation studies have looked to assess the performance of MAs methods in clinical trials targeting rare
events (see Table S1, online Appendix 1). However, these studies had mostly included methods based on exact
distributional assumptions, were limited to certain values of incidence and did not explicitly assess the perform-
ances of measurement error based on varying values of heterogeneity. For example, in one study,18 only methods
that include double-zero studies (i.e. studies which report no event in treatment and control arm) and avoid
continuity correction were included; and so the standard methods as outlined in the Cochrane handbook were not
of primary concern.8 The study only used small values for s2 (0–0.806) across the simulated scenarios, limiting the
knowledge for performances of the methods based on different heterogeneity values. A second study10 evaluated
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heterogeneity across three newly derived methods including a simple (unweighted) average treatment effect esti-
mator, a new heterogeneity estimator and a parametric bootstrapping test. Only two values of s2 (0 and 1.2) were
explored in this study which again limit the performance evaluation for higher levels of heterogeneity; and results
reveal that the new derived methods showed poor performance in their ability to detect heterogeneity anyway,
yielding biased overall treatment estimates. Another study19 using the same simple average method as in the
aforementioned study10 showed similar results with s2 fixed at 0.5. Other simulation studies19–22 assumed no
heterogeneity in the treatment effects, and three studies15,23,24 had used a real data set where the true effect and
heterogeneity levels were unknown, and hence the studies were limited in the context of comparing methods.
3 Statistical methods for MAs of rare data
The following methods described were used in our simulation study because they met our criteria: (i) simple to
implement (i.e. a lay trained person with basic MAs training could apply them), (ii) are mentioned in the Cochrane
handbook with the exception of the Peto/MH bootstrap methods and (iii) because of their accessibility in free
and/or mainstream statistical software such as RevMan, Stata or R.25–27
In each subsection heading, we provide the name of the method and, in the parentheses, its abbreviation in the
results figures/tables and the statistical software packages (with commands) can be used for parameter estimation.
The summations in all of the equations are over i, from 1 to the number of patients N, and k represents the total
number of studies, unless otherwise specified.
When analysing rare events and binary data in particular, the most commonly encountered effect measure used
in clinical trials is the OR. But, it is important to note that this effect measure is generally found to be approx-
imately the same as the relative risk when the outcome of interest is rare.28 However, because the Peto method is
only designed upon the OR, this prompted the use of OR for effect estimation throughout even though it is often
misinterpreted as being equivalent to the relative risk.29 But, it is worth noting that many of the other methods can
be analysed using relative risk.
In all MAs of k studies involving binary data, the results of each study can be presented in a 2 2 table (see
Table 1).
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se ln ORið Þ









3.1 Inverse-variance (IV) fixed effect (FE) and random effect (RE) [RevMan, R (meta,
metafor), Stata (metan)]
The inverse-variance method is the simplest approach to MAs, where the weights given to each study are the
inverse of the variance of the effect estimate (i.e. one over the square of its standard error). Thus, larger studies
which have smaller standard errors are given more weight than smaller studies, which have larger standard errors.
This choice of weight minimizes the imprecision (uncertainty) of the pooled effect estimate.
Table 1. Binary data from one trial.
Study k Event No event Total patients
Experimental ai bi n1i
Control ci di n2i
N
Note: i denotes the patient, k denotes the study and N denotes the total number of patients in that specific study.
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In the fixed-effects model, the weight (wi) is given as
wi ¼ 1
se dORi  2 (2)





se dORIVFE  ¼ 1ffiffiffiffiffiffiffiffiffiffiP
wi
p (4)
The heterogeneity statistic is given by the following formula
QIVFE ¼
X
wi dORi  dORIVFE 2
Under the null hypothesis that there are no differences in intervention effects among studies, this follows a chi-
squared distribution with k 1 degrees of freedom (where k is the number of studies contributing to the MAs). I2
is calculated as




In the random-effects analysis, each study is also weight by the inverse of it variance too, but the different is
that the variance now includes the original (within-studies) variance plus the between-studies variance, tau-
squared.
Concretely, under the random-effects model, the weight assigned to each study is
wi ¼ 1
Vi
where Vi is the within-study variance for study (i) plus the between-studies variance, tau-squared (s2Þ. That is
Vi ¼ Vi þ s2




where Ti is the observed effect calculated by
Ti ¼ ORi þ ei ¼ lþ Bi þ ei
The ORi is the true effect, and ei is the within study error. In turn, ORi is determined by the mean of all true
effects, l and the between-study error Bi.
The standard error of the combined effect is then
se dORIVRE  ¼ 1ffiffiffiffiffiffiffiffiffiffiP
wi
p (6)
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The heterogeneity statistic is given by the following formula
QIVRE ¼
X
wi Ti  dORIVRE 2
As is clearly outlined in the Cochrane handbook, because the IV method is based on large-sample variance
approximation, they are not intended for use with rare events.8 But for consistency, we included both the IV fixed
and random effects (IV-FE/IV-RE) in this simulation study as the baseline option. Whilst they have been shown
as poor performers globally, they have at times been shown to be useful when comparing the performances against
other methods.
3.2 Mantel–Haenszel
Unlike with IV methods, the MH estimation methods are considered the default fixed effect methods of MAs in
RevMan, and they use a different weighting scheme dependent upon which effect measure is used (e.g. ORs, risk
ratios and risk differences) to avoid the issue of normal approximation. MH is also preferred to inverse-variance
methods, as they have been shown to have better statistical properties when there are few events, which is common
among Cochrane and other reviews generally.
3.2.1 Classical Mantel–Haenszel (MH) [RevMan, R (meta, metafor), Stata (metan, metaan)]
The classical Mantel–Haenszel4 method is used specifically for log OR and OR. Here, the MH log OR is given by











where each study’s OR is given weight wMH;i ¼ biciNi , bi is the number of non-events in the intervention group, ci is
the number of events in the control group and Ni is the total number of patients as detailed in Table 1.
The log OR has standard error given by





















X ai þ dið Þaidi
N2i
;F ¼




X bi þ cið Þaidi
N2i
;H ¼
X bi þ cið Þbici
N2i
The heterogeneity test statistics is given by
QMH ¼
X
wi dORi  dORMH 2
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where dORi represents the log OR and wi are the weights wMH;i ¼ biciNi . Under the null hypothesis that there are no
differences in intervention effect among studies, this follows a chi-squared distributed with k1 degrees of
freedom.
The statistic I2 is calculated as




3.2.2 Mantel–Haenszel with fixed-effect weighting (MH-FE) [RevMan, R(meta, metafor), Stata (metaan)]
The MH-FE method differs to that of the classical MH method, with the use of a different weighting scheme.
Namely, the weight from equation (2) is used rather than the weight detailed in section 3.2.1. Then, the hetero-
geneity test statistics are the same but using this new weight.
3.2.3 Mantel–Haenszel with DL random-effects weighting (MH-DL) [RevMan, R (metafor), Stata (metaan)]
When data are sparse, either in terms of event rates being low or study size being small, the estimates of the
standard errors of the effect estimates that are used in the inverse-variance weighting can be poor. A variation on
the inverse-variance method is to incorporate an assumption that the different studies are estimating different, yet
related, intervention effects. This produces a random-effects MAs, and the simplest version is known as the
DerSimonian and Laird (DL) method.
The DL method is the oldest and most widely used random-effects MAs and has proven to be remarkably
robust in various scenarios.6
Effect sizes are assumed to have a distribution of ORi  N OR; s2
 
, and the estimate of s2 is given by
bs2DL ¼ max Q ðk 1ÞPk
i¼1 bwi Pki¼1cw2i =Pki¼1 bwi ; 0
( )
(9)
where the wi are the inverse-variance weights, calculated as w
0
i ¼ 1
se cORi 2, k is the number of studies contributing
to the MAs and Q is the heterogeneity statistic. For binary data, either QIVFE=RE or QMH may be taken. Both are
implemented in RevMan, and this is the only difference between random-effects methods under MH and IV
options.
Each study’s effect size is given by the weight
wi ¼ 1
se dORi 2 þds2DL (10)





se dORDL  ¼ 1ffiffiffiffiffiffiffiffiffiffiP
wi
p (12)
where the heterogeneity statistic Q is less than or equal to its degrees of freedom (k1), the estimate of the between
study variation, ds2DL , is zero, and the weights coincide with those given by the IV method.
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3.2.4 Mantel–Haenszel with bootstrapped DL random-effects weighting (MH-bDL) [R (metafor), Stata (metaan)]
Kontopantelis et al.12 recently suggested a non-parametric bootstrap version of the DL method (bDL) by
randomly sampling B sets of studies with replacement and then selecting the mean of the truncated
estimates. In each set, the MH effect size is estimated as explained in section 3.2.3, and s2 is estimated using
the DL method (bs2DLÞ from equation (9) and then is truncated if negative. bs2bDL is estimated as the mean of these
B estimates.17
Whilst the MH-bDL method is not recommended by Cochrane, it has been shown to be a good performer
in both detecting heterogeneity and returning more accurate overall effect estimates. However, its performance
has not yet been extensively assessed in rare event settings, and so it was important to include in our
simulation study.
3.3 Peto OR
3.3.1 Peto OR with fixed-effect weighting (Peto) [R (metafor), Stata (metan, metaan)]
Peto’s method5 can only be used to pool ORs. It uses an inverse-variance approach but utilizes an approximate
method of estimating the log OR and uses different weights.
The individual ORs are given by





where Xi is the ‘O – E’ observed minus expected statistic
Xi ¼ ai  E ai½ 
with the expected number of events in the experimental intervention group
E ai½  ¼ n1i ai þ cið Þ
Ni
and the hypergeometric variance of ai
Vi ¼ n1in2i ai þ cið Þ bi þ dið Þ
N2i Ni  1ð Þ
(14)
The logarithm of the OR has standard error
se ln ORPeto;ið Þ




Peto for combining summary log OR across studies is given by












where the odds ratio ORPeto;i is calculated using the approximated method described in equation (13), and Vi are
the hypergeometric variances described in equation (14).
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The heterogeneity statistic is given by
QPeto ¼
X
Vi lnORPeto;ið Þ2  lnORPetoð Þ2
n o
3.3.2 Peto OR with DL random-effects weighting (Peto-DL) [R (metafor or lme4), Stata (metaan)]
The summary Peto OR from section 3.3.1 is used for effect estimation, and bs2DL is estimated using equation (9).
3.3.3 Peto OR with bootstrapped DL random-effects weighting (Peto-bDL) [R (metafor), Stata (metaan)]
Again, equivalent to section 3.2.4, but this time using the s2 which is estimated using the DL method (bs2DLÞ from
equation (9), then bs2bDL is estimated as the mean of B estimates. bs2bDL is truncated if negative.
3.4 Excluded methods
The following methods were excluded because they either could not be accessed in RevMan or were not included
in the Cochrane guidelines: Binomial-normal hierarchical model,30 Poisson-normal hierarchical model,31 Poisson-
Gamma Hierarchical Model32 or Beta-binomial model,18 Bayesian MAs including weak informative priors,21
Exact method based on combining CIs,33 Logistic regression34,35 and Arcsine difference.36
4 Simulation setup
The data sets are generated under the ipdpower command in Stata37 which calculates the power for mixed-effects
aggregate (two-level) data from clinical trials. All definitions and calculations might be checked using the original
code (online Appendix 2). To mirror real data, true values for the design factors were gathered where possible,
from empirical data on performed MAs. Thus, the largest study to date includes 14,886 Cochrane reviews.38 Other
meta-analyses39–41 of rare events were also used to help inform on the design.
An important point to appreciate when designing and analysing of simulation studies is that they are empirical
experiments, meaning performance measures are themselves estimated, and estimates of performances are thus
subject to error. This feature of simulation studies is often not widely appreciated.42 The implications can be two-
fold. It is therefore important to present estimates of the simulation uncertainty in relation to bias and error
estimation of the methods and consider the number of repetitions needed.
Monte Carlo standard errors are key to quantifying simulation uncertainty by providing a standard error of
the estimate according to the number of simulations. We used this in our study to assess for simulation uncer-
tainty.43 The design factors for the simulation design are explained in section 4.1, and the measures used to assess
the performance of the methods and simulation uncertainty are explained in section 4.3.
4.1 Design factors
The following design factors were varied in the simulation study as follows:
• Number of patients in a single study: In a pivotal study that assessed the influence of trial sample size on binary
treatment effect estimates within 93 MAs (involving 735 individual trials),44 the observed trial sample sizes
varied among the MAs (median 34–2371 patients) and within MAs (e.g. trial sample size ranged from 106 to
48,835 patients in one MAs). With this in mind, we include sample size settings of 1500 to 50,000 patients
among MAs. We choose to fix the number of patients in the simulations to allow for more consistency when
reporting the results and when comparing across heterogeneity and the event incidence level.
• Number of studies per MAs: Given that the distribution of the number of studies in Cochrane38 and non-
Cochrane39 studies vary from on average 5 and 23, respectively. We selected a maximum of 20 studies in all
scenarios to avoid excessive simulation time. We also chose 3, 5, 7 and 10 studies for scenarios that would
reflect that similar of Cochrane reviews involving few studies in MAs.
• Degree of heterogeneity: Between-study variance (s2) on its own is perhaps not an efficient way to quantify
heterogeneity, since the within variance estimate component (r2) cannot be ignored. In logistic regression
within Stata, the within-variance component is fixed to u2/3 or 3.289668, which is central to the data generation
mechanism with ‘ipdpower’.
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Given s2¼ (I2u2/3)/(100 I2), then if
• I2¼0% (no heterogeneity), then s2¼0.822467
• I2¼20% (small heterogeneity), then s2¼0.822467
• I2¼50% (medium heterogeneity), then s2¼3.289868
• I2¼90% (high heterogeneity), then s2¼29.60881
Because other reviews10,18,22 have focused only on small values of heterogeneity, we therefore included sce-
narios of a higher degree of heterogeneity for complete coverage in meta-analyses, especially since heterogeneity
tends to be underestimated.12
• Probability of membership for the intervention and control (denoted as r): For the treatment and control arm
randomisation, we considered both 1:1 allocation (r¼ 0.5) and unbalanced allocations favouring intervention
by r¼ 0.1 (10%–90%). Although a review paper has shown that 78% of clinical trials were conducted with
equal patient allocation strategies,45 we include imbalanced allocation due to the unpredictable performances
associated with Peto OR.1
• Incidence of event: We considered three different frequencies of rare events, Rare (0.01% to< 0.1%), Very
rare (<0.01%) and Common (1% to< 10%) as defined by the World Health Organisations Council for
International Organizations of Medical Sciences,46 European Medicines Agency47 and the Food and Drug
Administration.48
• Treatment effect-size: In all simulation settings, we imagined the situation of MAs with the outcome being a
rare adverse (or sparse) event where the treatment is aiming for a further lowering of events as compared with
the control. As such, we consider the null hypothesis with an OR of 1 as the true treatment effect in the ‘no
effect’ situation. In the medium effect situation, we use an OR of ln (0.5)¼0.69, which corresponds to the
median OR from Turner et al.38
4.2 Simulation scenarios
Details of the simulation scenarios are shown in Table 2. In total, there were 360 MAs scenarios, each involving
1000 iterations to reduce simulation error. Due to the high number of iterations, it was necessary to use sophis-
ticated in-house high-computational clustering to enable a wider range of scenarios.
4.3 Evaluating simulation performance
The following five measures were used to assess the performance of the nine methods on the simulated scenarios:
• Mean error is calculated as the aggregate of the ‘absolute difference’ in the estimate of treatment effect to the












• Coverage measures the percentage of the true treatment effects included in the available 95% confidence
intervals over all generated data. This should theoretically be close to 95%.
• Power indicates the percentage of iterations in which a model coefficient was found to be statistically significant
and in the hypothesized direction. Information is then aggregated across all simulated datasets to approximate
the overall power.
• Coverage and power is a combined average across both measures. Because they are interlinked, it is fundamen-
tal and important to assess them simultaneously in this study.
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5 Results
We present the results on the five performance measures separately, and in the final part, we provide a summary
for application of the methods for practitioners.
5.1 Mean bias
For MAs involving ‘rare events’ with imbalanced patient randomisation to each treatment group (r¼ 0.1), the
results show that when there is no heterogeneity, the pattern of mean bias is consistently low across all of the
methods (Figure 1). However, with heterogeneity increasing, the mean bias performance worsened. The MH-DL
and MH-bDL methods maintained the lowest levels of bias among greater levels of heterogeneity; this was true
across all sample size settings. In MAs with a balanced treatment allocation ratio (r¼ 0.5) (online Figure S1), the
mean bias was more modest across all values of heterogeneity, but the pattern was similar to MAs with imbal-
anced treatment ratio, with the exception of when heterogeneity was around 90%, where Peto-DL and Peto-bDL
resulted in the lowest bias estimate. In MAs involving ‘very rare’ events unsurprisingly, the mean bias was greater
across all methods and all values of heterogeneity (online Figures S2 and S3). However, in MAs displaying zero
heterogeneity, Peto, Peto-DL, Peto-bDL and MH methods maintained the lowest mean bias; and in MAs with
high levels of heterogeneity, only Peto-DL/bDL were able to maintain low desirable levels of bias. For
non-rare events, the mean bias was similar but was higher across the different values of heterogeneity (online
Figures S4 and S5).
5.2 Mean error
The performance based on mean error was almost identical across both treatment allocation settings, and the
mean error and heterogeneity estimates were positively associated as they increased. For MAs with balanced
treatment allocations and involving rare events (Figure 2), the Peto-DL and Peto-bDL methods maintained the
lowest mean error. This was more prevalent amongst MAs presenting with higher levels of heterogeneity. In
contrast, MAs involving imbalanced treatment allocations (online Figure S6) revealed that MH-DL and MH-
bDL were preferred. For very rare events, the mean error performance was similar in either treatment allocation
setting; but the error rate was greater across all sample size settings than observed within MAs of rare events
(online Figures S7 and S8). For none-rare events, the pattern remained consistent and the level of error was
smaller than that observed for rare and very rare event settings (online Figures S9 and S10).






of studies Between-study variance (s2)a
Incidence rate of rare





1 1500 3 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
2 2500 5 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
3 3000 3 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
4 3500 7 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
5 5000 5 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
6 5000 10 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
7 7000 7 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
8 7500 3 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
9 10000 10 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
10 10000 20 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
11 12500 5 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
12 17500 7 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
13 20000 20 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
14 25000 10 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
15 50000 20 0/0.822467/3.289868/29.60881 1/1000; 1/10000; 1/10 0.5/0.1
aEach of the parameters for heterogeneity, incidence and membership probability were simulated across all 15 scenarios.
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5.3 Coverage
In the absence of heterogeneity, the performance of the methods based on coverage in MAs with rare events was
consistently higher than the 95% level in all four methods (MH-DL, MH-bDL, Peto-DL and Peto-bDL).
Performance was considerably better in MAs with balanced treatment allocation (Figure 3). Unsurprisingly,
for high levels of heterogeneity, only the DL random-effects methods were able to maintain a coverage above
50%, this was true in both treatment allocation settings (see online Figure S11 for imbalanced setting). For MAs
involving very rare events with balanced treatment allocation, the results were similar to that of MAs with rare
events (online Figure S12). However, in MAs involving an imbalanced treatment allocation, the coverage varied
somewhat across the different sample size settings and for different values of heterogeneity (online Figure S13).
The best coverage across all sample size settings and heterogeneity scenarios were maintained by the Peto-DL and
Peto-bDL. Coverage performance in non-rare events is shown in online Figures S14 and S15.
5.4 Power
The performances based on power in MAs involving rare events show that all methods are able to maintain 80%
power or above when minimal heterogeneity is present. This was particularly true in MAs with balanced
Figure 1. Mean bias of rare event scenarios with imbalanced treatment allocation (r¼ 0.1). The percentage values on the y-axis
represent the heterogeneity group, i.e. 0%, 20%, 50% and 90%. The value within these groups on the y-axis represents the number of
patients/studies in each meta-analysis scenario. All other scenarios are provided in the online Appendix. IV: inverse variance; FE: fixed
effect;RE: random effect; DL: DerSimonian and Laird; MH: Mantel–Haenszel; bDL: bootstrapped DL.
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treatment allocations (Figure 4). However, the performance was less consistent in MAs with lower sample sizes
and imbalanced treatment allocation (online Figure S16). For example, when heterogeneity was above 20%, this
resulted in a power below 30% across all methods. In the smaller sample size settings, the standard MH and Peto
methods performed well. In MAs involving very rare events, the power was far less robust and was seen as
insufficient. For example, in MAs involving imbalanced treatment allocations, the power to detect a true event
failed to exceed 20% in most settings (Figure 5). In contrast, the performance in MAs involving balanced treat-
ment allocations was moderately better when heterogeneity was below 20% (online Figure S17). The results for
non-rare events are shown in online Figures S18 and S19.
5.5 Convergence
All 360 simulated MAs scenarios successfully converged across all methods (online Figures S20 to S25), and
therefore, non-convergence was not an issue for this simulation study. Results for the 360 scenarios are provided
in the online Appendix.
5.6 Making informed decisions about which methods to use in certain scenarios
In this section, we evaluate the methods used in this simulation study and discuss which are best suited for specific
MAs settings. The preferred choice of the methods should always be based on the performances due to coverage
Figure 2. Mean error for rare event scenarios with balanced treatment allocation (r¼ 0.5). IV: inverse variance; FE: fixed effect; RE:
random effect; DL: DerSimonian and Laird; MH: Mantel–Haenszel; bDL: bootstrapped DL.
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and power combined. As the primary concern in MAs of safety should be to discern whether there is any signal of
harm in the data, coverage and power are therefore of most importance. The results of coverage and power
combined for rare, very rare and non-rare event settings are shown in online Figures S26 to S31.
The most optimal performing methods based on incidence and heterogeneity in MAs involving balance treat-
ment allocations are presented in Table 3. For rare events, the Peto-bDL or Peto-DL methods performed best in
MAs with lower sample size (3500 patients) settings and when small-to-moderate heterogeneity (0%–50%) were
present. When higher values of heterogeneity were present, the MH-bDL method was preferred over Peto. This
was especially true when the sample size was above 3500 patients. In MAs involving very rare events, the pattern
was similar to that of rare events. However, Peto-bDL was the preferred method in higher sample size settings.
For non-rare events, there was no obvious preferred method in the absence of heterogeneity. Otherwise, when
heterogeneity was present, MH-DL or MH-bDL was preferred.
In MAs involving imbalanced treatment allocations (online Table S2), the trend of the performance was
remarkably similar. However, the Peto methods performed well in rare event MAs with sample size settings of
up to 5000 patients. In larger sample size settings above 5000 patients with higher levels of heterogeneity, MH-
bDL was preferred. For very rare event MAs, Peto-bDL was clearly the most optimal method across all of the
design features; and for non-rare event MAs, the Peto-bDL was preferred among smaller sample size settings
(<3500 patients) and MH-bDL for larger samples (3500 patients). One notable and important observation was
Figure 3. Coverage of rare event scenarios in meta-analysis with balanced treatment allocation (r¼ 0.5). IV: inverse variance; FE:
fixed effect;RE: random effect; DL: DerSimonian and Laird; MH: Mantel–Haenszel; bDL: bootstrapped DL.
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that none of the methods were able to achieve above 50% coverage and power whilst heterogeneity levels exceeded
50% in rare event MAs, and 20% in very rare event MAs.
6 Discussion
Our results show that some methods used for MAs of rare events can perform better than others under certain
samples size settings, incidence and levels of heterogeneity. In MAs involving rare events with no heterogeneity,
coverage and power revealed very small performance-based differences between the methods. In very rare event
MAs displaying no heterogeneity, the Peto-bDL method performed best across all sample sizes. However, when
heterogeneity was above 20%, convergence and power failed to exceed 50% performance – which only worsened
as heterogeneity increased. There was a similar trend in MAs involving rare events, where the Peto-bDL was the
preferred method, but this was only true in MAs with smaller sample sizes. In MAs involving medium-to-large
sample sizes, MH-bDL generally outperformed the other methods.
The error associated with the methods measured by mean bias and mean error was almost identical across all
methods in MAs of rare incidence. However, as the mean bias and mean error increased, this trend was closely
associated with increased levels of heterogeneity. In general, the MH-bDL method was able to achieve the lowest
bias and error in MAs of rare events. However, in MAs involving very rare events, the Peto-DL and Peto-bDL
Figure 4. Power of rare event scenarios in meta-analysis with balanced treatment allocation (r¼ 0.5). IV: inverse variance; FE: fixed
effect;RE: random effect; DL: DerSimonian and Laird; MH: Mantel–Haenszel; bDL: bootstrapped DL.
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methods maintained better performances. A cautious approach is needed when MAs differ between balanced and
imbalanced treatment allocations, where we have shown that using MH-DL and MH-bDL rather than Peto
method is preferred in MAs with imbalanced treatment allocations.
6.1 Strengths and limitations
We have performed the largest simulation study on rare event meta-analyses to date including 360 realistic data
sets with varied incidence rates, sample size settings, allocation of patients by treatment group and heterogeneity.
We also include four newly proposed methods (MH-DL, MH-bDL, Peto-DL and Peto-bDL) which have not been
used before in rare event MAs and are not specific to the Cochrane guidelines.
Despite these strengths, there remain several limitations. First, whilst our simulation study was restricted to the
use of mostly the mainstream Cochrane recommended methods that are easily accessible and regularly used
amongst the systematic review community. We are aware that improved performances have been shown in
some of the more advanced statistical methods based on exact distributional assumptions.18,21,30–32 Such methods
are designed on the principles of the inclusion of single zero or double zero events.15,20 But, there are several
drawbacks to using these methods such as (i) they are not available in RevMan and therefore are not being used
widespread among the Cochrane community, (ii) they are not included in any of the main guidelines for
Figure 5. Power of very rare event scenarios with imbalanced treatment allocation (r¼ 0.1). IV: inverse variance; FE: fixed effect; RE:
random effect; DL: DerSimonian and Laird; MH: Mantel–Haenszel; bDL: bootstrapped DL.
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performing MAs,8,49 (iii) they rely upon authors reporting zero case events in their primary report, potentially
precluding their inclusion in MAs in the first place and (iv) they require an understanding of statistical modelling
based on distributions or Bayesian inference,18 which is another reason for their poor uptake, as the practitioner
may not be statistically astute to such methods without adequate training.7 We also did not include some of the
more recent methods that have only just be added to the Stata package ‘metan’,50 which include likelihood-based
methods such as profile likelihood and the Bartlett and Skivgaard corrections to the likelihood. Both have been
used in an earlier study,51 but showed little improvement in MAs involving common events.
Second, we only include methods which include the OR and did not consider other measures like relative risk
or risk differences. Whilst OR is considered to have the best statistical properties in the case of the Peto OR, it
is often misinterpreted as a relative risk, and authors might opt for the use of other effect measures that are easier
to interpret.18
Finally, measurement errors can often complicate interpretation of the results by potentially concealing impor-
tant differences between groups or by indicating differences, which, in reality, do not exist. The total measurement
error is generally partitioned into two separate classes of error: systematic and random.52 Systematic errors (also
known as ‘bias’) are reproducible inaccuracies that lead to a measured value that is consistently larger or smaller
than the true value. Random errors lead to variable differences from the true value and give rise, unpredictably, to
measurements that are greater or smaller than the true value. Random errors can be reduced by averaging over a
number of observations and observing the Monte Carlo standard error. However, if the number of simulations
is not large enough, it is likely that differences in point estimates (such as coverage and power) are due to
Table 3. Lookup table for optimal method(s) based on coverage and power for MAs involving balanced allocation ratio (r¼ 0.5).
s2
0% 20% 50% 90%
Sample size setting
(patients/studies)
1500/3 VR¼Peto VR¼Peto-bDL VR¼Peto-bDL VR¼Peto-bDL
R¼Peto R¼Peto-bDL R¼Peto-bDL R¼MH-bDL
NR¼Not obvious NR¼Peto-DL NR¼Peto-bDL NR¼MH-bDL
2500/5 VR¼Peto VR¼Peto-bDL VR¼Peto-bDL VR¼MH-bDL
R¼Peto R¼Peto-DL R¼Peto-bDL R¼MH-bDL
NR¼Not obvious NR¼MH-DL NR¼MH-DL NR¼MH-bDL
3000/3 VR¼Peto VR¼Peto-bDL VR¼Peto-bDL VR¼MH-bDL
R¼Peto R¼Peto-DL R¼Peto-bDL R¼MH-bDL
NR¼Not obvious NR¼Peto-DL NR¼Peto-bDL NR¼MH-bDL
3500/7 VR¼MH VR¼Peto-bDL VR¼Peto-bDL VR¼MH-bDL
R¼MH-bDL R¼Peto-bDL R¼Peto-bDL R¼MH-bDL
NR¼Not obvious NR¼MH-DL NR¼MH-DL NR¼MH-bDL
5000/5 VR¼Peto/MH VR¼Peto-DL VR¼Peto-bDL VR¼MH-bDL
R¼MH-bDL R¼MH-DL R¼MH-bDL R¼MH-bDL
NR¼Not obvious NR¼MH-DL NR¼MH-DL NR¼Peto-bDL
5000/10 VR¼MH VR¼Peto-bDL VR¼Peto-bDL VR¼MH-bDL
R¼MH-bDL R¼MH-DL R¼MH-bDL R¼MH-bDL
NR¼Not obvious NR¼MH-DL NR¼MH-DL NR¼Peto-bDL
7000/7 VR¼MH VR¼Peto-bDL VR¼Peto-bDL VR¼MH-bDL
R¼MH-bDL R¼MH-DL R¼MH-DL R¼MH-bDL
NR¼Not obvious NR¼MH-DL NR¼MH-DL NR¼Peto-bDL
10000/10 VR¼MH VR¼Peto-DL VR¼Peto-bDL VR¼MH-bDL
R¼MH-bDL R¼MH-DL R¼MH-DL R¼MH-bDL
NR¼Not obvious NR¼MH-DL NR¼MH-DL NR¼MH-bDL
10000/20 VR¼MH VR¼Peto-bDL VR¼Peto-bDL VR¼Peto-bDL
R¼Peto-bDL R¼MH-DL R¼MH-bDL R¼MH-bDL
NR¼Not obvious NR¼MH-DL NR¼MH-bDL NR¼MH-bDL
20000/20 VR¼MH VR¼Peto-bDL VR¼Peto-bDL VR¼MH-bDL
R¼MH-bDL R¼MH-bDL R¼MH-bDL R¼MH-bDL
NR¼Not obvious NR¼MH-DL NR¼MH-DL NR¼MH-bDL
VR: very rare; R: rare; NR: non-rare.
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random/simulation error.37 Nevertheless, we are confidence whilst averaging the performance measures over 1000
iterations that this is large enough to avoid the potential caveat of random error.
6.2 Implications for future practice
Not surprisingly, the random-effects model DL was the preferred method from our simulation analysis, as they
are more general models as compared with their fixed-effect counterparts. As such, our work is a convenient and
important extension of some of the most recent simulation studies for MAs with rare events.1,10,14 These earlier
efforts mainly concentrated on the standard fixed-effect methods and were unable to include the more recent MH
and Peto DL weighted schemes; and in particular, the non-parametric bootstrap extensions of DL which are not
recommended in the guidelines. The bootstrapped DL had been seen to perform well overall despite its larger
heterogeneity bias for small MAs12,17; however, its performance based on rare events remained relatively
unknown until know. Here, we show that the bootstrap DL extensions for both Peto and MH generally outper-
form the other methods. This was particularly true based on the performances for coverage and power. Therefore,
we stress the importance for further research to assess the wider use of these methods for when synthesising rare
event data and recommend that any future updates of the guidelines should reflect these findings to encourage
their uptake.
Over the last decade, there has been overwhelming support of methods which aim to include double zero
studies without continuity correction by applying exact distributional assumptions instead of approximate like-
lihood. It has been shown that these methods can lead to reduced bias when such data are reported in the primary
report. The most recent update of the Cochrane guidelines in 201953 now give some credence to the existence of
these methods. Whilst the methods do clearly hold some promise, they are still not being used widespread in the
research community; as one study had recently shown.7 There are several reasons for this, firstly, they are still in
their infancy stage of development, and therefore are not readily available in mainstream statistical software used
for performing MAs. Secondly, is of course the fact that researchers are likely to take a rather dogmatic approach
when zero events are present and simply apply a risk difference in a sensitivity analysis or apply some sort of
continuity correction, or beyond they may just delete double zero studies from their data precluding their inclu-
sion in a MAs. One thing that remains unclear is that when working with published results, whether the failure to
mention a particular adverse event means there were no such events, or simply that such events were not included
as a measured endpoint.54 Meta-analysts need not only clear and more precise guidance, but there should also be a
policy requirement for reporting studies with no events by considering ‘joint reporting’ of clinical endpoints and
safety events in clinical trials.55,56
A major fragility when performing MAs of rare events is that most of the included trials are not adequately
powered to detect an effect on the event of interest such is the case for adverse events.37,57 This issue mostly arises
because adverse events are often defined as secondary outcomes of interest in the study. Applied analysts need to
think more critically about whether random-effects meta-analyses, when applied to highly heterogeneous datasets
with very few studies or events, are likely to provide more power than individual studies. Power calculations are
an important component of research grant proposals, but are rarely used in practice.58–60 There are several
software options available for performing simple and quick power calculations. For example, in Stata, there is
the ‘power’ command which enables robust calculations including power estimation for cluster randomised con-
trolled trials.61 There is also a similar command in R (‘clusterPower’) which allows for exactly the same calcu-
lation.62 Recent supporting evidence for power calculations suggests that at least five or more studies are needed
to reasonably consistently achieve powers from random-effects MAs.57 But, because this was based on MAs of
common events, the statistical inferences in our study which are drawn from MAs with very few studies and/or
events means that MAs are likely to be considered even less worthwhile. Further research is desperately needed
into power assumptions when the data are sparse.
6.3 Conclusions
To conclude in MAs of rare binary outcomes, we have shown that the Peto-bDL or Peto-DL was most effective in
both rare and very rare event settings, with the exception of MAs involving medium-to-large sample sizes where
MH-bDL is preferred. In cases where heterogeneity is large, performance estimation based on coverage and power
was mostly insufficient. Here, we advise analysts to think more critically about their MAs approach, when applied
to highly heterogeneous datasets with very few events, and we strongly encourage the use of power calculations
before considering a MAs. Whilst this simulation study has clearly shown that some of the methods that are used
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less often in MAs do appear to have good properties under sparse data scenarios, we urge the need for further
work to assess the methods alongside more complex distributional-based methods in future simulation or empir-
ical studies.
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